Diamyd Medical (Sweden) Investor Sentiment

DMYD-B Stock  SEK 13.60  0.62  4.78%   
About 54% of Diamyd Medical's investors are presently thinking to get in. The analysis of current outlook of investing in Diamyd Medical AB suggests that some traders are interested regarding Diamyd Medical's prospects. The current market sentiment, together with Diamyd Medical's historical and current headlines, can help investors time the market. In addition, many technical investors use Diamyd Medical AB stock news signals to limit their universe of possible portfolio assets.
  
over a week ago at news.google.com         
Penser reiterates fair value for Diamyd Medical after recruitment milestone - Marketscreener.com
Google News at Macroaxis
over two weeks ago at news.google.com         
Diamyd Medicals auditors assess that the company may need additional financing - Marketscreener.com
Google News at Macroaxis
over three weeks ago at news.google.com         
Diamyd Medicals Board of Directors proposed for re-election - Marketscreener.com
Google News at Macroaxis
over two months ago at news.google.com         
Penser raises motivated value for Diamyd after FDA news - Marketscreener.com
Google News at Macroaxis
over three months ago at news.google.com         
Diamyd Medical Previous findings from a clinical trial with Remygen are discussed as part of a lectu...
Google News at Macroaxis
over three months ago at news.google.com         
Diamyd Medical AB Receives Second U.S. FDA Fast Track Designation for Diamyd - for the Prevention of...
Google News at Macroaxis
over three months ago at news.google.com         
Diamyd Medical Reports Third Quarter 2024 Earnings - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Type 1 Diabetes Market Report 2032- Latest FDA, EMA, PDMA, Pipeline Therapies, Epidemiology - Barcha...
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical Positive safety evaluation of Remygen in high dose and in combination with Alprazolam...
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical patent for intralymphatic injection of GAD in autoimmune diabetes to be granted in Ch...
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
FDA Pauses Start of DIAGNODE-3 of Diamyd Medical in the US Pending Clarification on Study Drug - Mar...
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical AB Publ Reports Earnings Results for the Fourth Quarter Ended August 31, 2021 - Marke...
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2022 - Marketscre...
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023 - Marketscr...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Diamyd Medical that are available to investors today. That information is available publicly through Diamyd media outlets and privately through word of mouth or via Diamyd internal channels. However, regardless of the origin, that massive amount of Diamyd data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Diamyd Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Diamyd Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Diamyd Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Diamyd Medical alpha.

Diamyd Medical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Diamyd Stock analysis

When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance